FDA Requiring Lower Starting Dose for Lunesta (Eszopiclone)

Posted on May 15, 2014 by

Risk of impairment the morning after use of sleep aid drugs

The U.S. Food and Drug Administration has finally announced that the sleep drug Lunesta (eszopiclone) should be prescribed, initially, at a lower recommended starting dose. This is due to many factors, but possibly the most important is that eszopiclone levels in some patients may be too high. This has been studied due to women being prescribed the same amounts as men, even though there is data to suggest women process medications at different rates than men, and may be more susceptible to accidental overdoses. Eszopiclone was found at levels high enough, in the morning after use, to impair activities that require alertness, including driving, even if they feel fully awake. There have been a number of accidents where the at-fault driver was under the influence of a sleeping aid taken the night before.

Additional Information About Lunesta (Eszopiclone)

Lunesta Safety Announcement

Additional Information for Health Care Professionals

 

Copyright © 2017 MLG | Referrals | Privacy Policy | Disclaimer | Sitemap